Cargando…
Disparate Impact of Butyroyloxymethyl Diethylphosphate (AN-7), a Histone Deacetylase Inhibitor, and Doxorubicin in Mice Bearing a Mammary Tumor
The histone deacetylase inhibitor (HDACI) butyroyloxymethyl diethylphosphate (AN-7) synergizes the cytotoxic effect of doxorubicin (Dox) and anti-HER2 on mammary carcinoma cells while protecting normal cells against their insults. This study investigated the concomitant changes occurring in heart ti...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3285631/ https://www.ncbi.nlm.nih.gov/pubmed/22384017 http://dx.doi.org/10.1371/journal.pone.0031393 |
_version_ | 1782224496387686400 |
---|---|
author | Tarasenko, Nataly Cutts, Suzanne M. Phillips, Don R. Inbal, Aida Nudelman, Abraham Kessler-Icekson, Gania Rephaeli, Ada |
author_facet | Tarasenko, Nataly Cutts, Suzanne M. Phillips, Don R. Inbal, Aida Nudelman, Abraham Kessler-Icekson, Gania Rephaeli, Ada |
author_sort | Tarasenko, Nataly |
collection | PubMed |
description | The histone deacetylase inhibitor (HDACI) butyroyloxymethyl diethylphosphate (AN-7) synergizes the cytotoxic effect of doxorubicin (Dox) and anti-HER2 on mammary carcinoma cells while protecting normal cells against their insults. This study investigated the concomitant changes occurring in heart tissue and tumors of mice bearing a subcutaneous 4T1 mammary tumor following treatment with AN-7, Dox, or their combination. Dox or AN-7 alone led to inhibition of both tumor growth and lung metastases, whereas their combination significantly increased their anticancer efficacy and attenuated Dox- toxicity. Molecular analysis revealed that treatment with Dox, AN-7, and to a greater degree, AN-7 together with Dox increased tumor levels of γH2AX, the marker for DNA double-strand breaks and decreased the expression of Rad51, a protein needed for DNA repair. These events culminated in increased apoptosis, manifested by the appearance of cytochrome-c in the cytosol. In the myocardium, Dox-induced cardiomyopathy was associated with an increase in γH2AX expression and a reduction in Rad51 and MRE11 expression and increased apoptosis. The addition of AN-7 to the Dox treatment protected the heart from Dox insults as was manifested by a decrease in γH2AX levels, an increase in Rad51 and MRE11 expression, and a diminution of cytochrome-c release. Tumor fibrosis was high in untreated mice but diminished in Dox- and AN-7-treated mice and was almost abrogated in AN-7+Dox-treated mice. By contrast, in the myocardium, Dox alone induced a dramatic increase in fibrosis, and AN7+Dox attenuated it. The high expression levels of c-Kit, Ki-67, c-Myc, lo-FGF, and VEGF in 4T1 tumors were significantly reduced by Dox or AN-7 and further attenuated by AN-7+Dox. In the myocardium, Dox suppressed these markers, whereas AN-7+Dox restored their expression. In conclusion, the combination of AN-7 and Dox results in two beneficial effects, improved anticancer efficacy and cardioprotection. |
format | Online Article Text |
id | pubmed-3285631 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2012 |
publisher | Public Library of Science |
record_format | MEDLINE/PubMed |
spelling | pubmed-32856312012-03-01 Disparate Impact of Butyroyloxymethyl Diethylphosphate (AN-7), a Histone Deacetylase Inhibitor, and Doxorubicin in Mice Bearing a Mammary Tumor Tarasenko, Nataly Cutts, Suzanne M. Phillips, Don R. Inbal, Aida Nudelman, Abraham Kessler-Icekson, Gania Rephaeli, Ada PLoS One Research Article The histone deacetylase inhibitor (HDACI) butyroyloxymethyl diethylphosphate (AN-7) synergizes the cytotoxic effect of doxorubicin (Dox) and anti-HER2 on mammary carcinoma cells while protecting normal cells against their insults. This study investigated the concomitant changes occurring in heart tissue and tumors of mice bearing a subcutaneous 4T1 mammary tumor following treatment with AN-7, Dox, or their combination. Dox or AN-7 alone led to inhibition of both tumor growth and lung metastases, whereas their combination significantly increased their anticancer efficacy and attenuated Dox- toxicity. Molecular analysis revealed that treatment with Dox, AN-7, and to a greater degree, AN-7 together with Dox increased tumor levels of γH2AX, the marker for DNA double-strand breaks and decreased the expression of Rad51, a protein needed for DNA repair. These events culminated in increased apoptosis, manifested by the appearance of cytochrome-c in the cytosol. In the myocardium, Dox-induced cardiomyopathy was associated with an increase in γH2AX expression and a reduction in Rad51 and MRE11 expression and increased apoptosis. The addition of AN-7 to the Dox treatment protected the heart from Dox insults as was manifested by a decrease in γH2AX levels, an increase in Rad51 and MRE11 expression, and a diminution of cytochrome-c release. Tumor fibrosis was high in untreated mice but diminished in Dox- and AN-7-treated mice and was almost abrogated in AN-7+Dox-treated mice. By contrast, in the myocardium, Dox alone induced a dramatic increase in fibrosis, and AN7+Dox attenuated it. The high expression levels of c-Kit, Ki-67, c-Myc, lo-FGF, and VEGF in 4T1 tumors were significantly reduced by Dox or AN-7 and further attenuated by AN-7+Dox. In the myocardium, Dox suppressed these markers, whereas AN-7+Dox restored their expression. In conclusion, the combination of AN-7 and Dox results in two beneficial effects, improved anticancer efficacy and cardioprotection. Public Library of Science 2012-02-23 /pmc/articles/PMC3285631/ /pubmed/22384017 http://dx.doi.org/10.1371/journal.pone.0031393 Text en Tarasenko et al. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited. |
spellingShingle | Research Article Tarasenko, Nataly Cutts, Suzanne M. Phillips, Don R. Inbal, Aida Nudelman, Abraham Kessler-Icekson, Gania Rephaeli, Ada Disparate Impact of Butyroyloxymethyl Diethylphosphate (AN-7), a Histone Deacetylase Inhibitor, and Doxorubicin in Mice Bearing a Mammary Tumor |
title | Disparate Impact of Butyroyloxymethyl Diethylphosphate (AN-7), a Histone Deacetylase Inhibitor, and Doxorubicin in Mice Bearing a Mammary Tumor |
title_full | Disparate Impact of Butyroyloxymethyl Diethylphosphate (AN-7), a Histone Deacetylase Inhibitor, and Doxorubicin in Mice Bearing a Mammary Tumor |
title_fullStr | Disparate Impact of Butyroyloxymethyl Diethylphosphate (AN-7), a Histone Deacetylase Inhibitor, and Doxorubicin in Mice Bearing a Mammary Tumor |
title_full_unstemmed | Disparate Impact of Butyroyloxymethyl Diethylphosphate (AN-7), a Histone Deacetylase Inhibitor, and Doxorubicin in Mice Bearing a Mammary Tumor |
title_short | Disparate Impact of Butyroyloxymethyl Diethylphosphate (AN-7), a Histone Deacetylase Inhibitor, and Doxorubicin in Mice Bearing a Mammary Tumor |
title_sort | disparate impact of butyroyloxymethyl diethylphosphate (an-7), a histone deacetylase inhibitor, and doxorubicin in mice bearing a mammary tumor |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3285631/ https://www.ncbi.nlm.nih.gov/pubmed/22384017 http://dx.doi.org/10.1371/journal.pone.0031393 |
work_keys_str_mv | AT tarasenkonataly disparateimpactofbutyroyloxymethyldiethylphosphatean7ahistonedeacetylaseinhibitoranddoxorubicininmicebearingamammarytumor AT cuttssuzannem disparateimpactofbutyroyloxymethyldiethylphosphatean7ahistonedeacetylaseinhibitoranddoxorubicininmicebearingamammarytumor AT phillipsdonr disparateimpactofbutyroyloxymethyldiethylphosphatean7ahistonedeacetylaseinhibitoranddoxorubicininmicebearingamammarytumor AT inbalaida disparateimpactofbutyroyloxymethyldiethylphosphatean7ahistonedeacetylaseinhibitoranddoxorubicininmicebearingamammarytumor AT nudelmanabraham disparateimpactofbutyroyloxymethyldiethylphosphatean7ahistonedeacetylaseinhibitoranddoxorubicininmicebearingamammarytumor AT kesslericeksongania disparateimpactofbutyroyloxymethyldiethylphosphatean7ahistonedeacetylaseinhibitoranddoxorubicininmicebearingamammarytumor AT rephaeliada disparateimpactofbutyroyloxymethyldiethylphosphatean7ahistonedeacetylaseinhibitoranddoxorubicininmicebearingamammarytumor |